Oncotest’s Post

At #AmplityHealth, our contract sales, medical, and communications experts have a front-row seat in advancing #immunotherapy and #precisionmedicine to combat cancer more effectively with our biopharma clients. Here are some key highlights from #ASCO24 Day 1: - Discussion of newly FDA-approved oncology agents - Presentation of 5 years of data from the CROWN study comparing lorlatinib and crizotinib in new patients with advanced ALK-positive non-small cell lung cancer - Analysis of research into whether circulating tumor DNA can help predict the effectiveness of neoadjuvant chemotherapy and evaluate the prognosis for those with early breast cancer View our full Day 1 summary and join our mailing list for updates: https://lnkd.in/gA3s6Gh7

At #AmplityHealth, our contract sales, medical, and communications experts have a front-row seat in advancing #immunotherapy and #precisionmedicine to combat cancer more effectively with our biopharma clients. Here are some key highlights from #ASCO24 Day 1: - Discussion of newly FDA-approved oncology agents - Presentation of 5 years of data from the CROWN study comparing lorlatinib and crizotinib in new patients with advanced ALK-positive non-small cell lung cancer - Analysis of research into whether circulating tumor DNA can help predict the effectiveness of neoadjuvant chemotherapy and evaluate the prognosis for those with early breast cancer View our full Day 1 summary and join our mailing list for updates: https://lnkd.in/euzvmUPG

Learn how to approach biomarker testing in lung and prostate cancer with real clinical example cases. In this on-demand webinar, three renowned experts, Prof. Fernando López-Ríos, Assoc. Prof. Alicia Morgans and Assoc. Prof. Herbert Loong, guide you through the difficulties and considerations of biomarker testing. PLUS, you can take the optional e-Learning to gain CME credits. Find it here: https://ow.ly/5hhC50TzQ4p This educational programme is supported by an Independent Educational Grant from AstraZeneca and Amoy Diagnostics. #MedEd #IndependentMedEd #Oncology #LungCancer #ProstateCancer #PrecisionMedicine

#ESMOBreast24: Learn how to integrate innovation into your daily practice and improve patient outcomes. Register by 📅17 April for preferential rates and see you in Berlin, Germany, or online. 🔗https://ow.ly/TqWT50QYvNh During this event, you will be able to: ➡️ Understand recent developments in novel diagnostics, biomarkers and treatments in breast cancer ➡️ Be updated on the rapid development of novel antibody drug conjugates for breast cancer ➡️ Gain insights on new strategies for Luminal, HER2 positive, HER2-low and triple negative breast cancer ➡️ Understand special considerations for different subgroups of patients with breast cancer

🇳🇴 Norway's precision medicine revolution is taking the fight to cancer! Discover how biotech companies like Nykode Therapeutics are teaming up with global pharma to develop innovative cancer vaccines and therapies. The IMPRESS-Norway clinical trial is paving the way for improved public cancer care through precision medicine. Want to know more about Norway's thriving ecosystem and its impact on cancer treatment? Click to learn more👇 #PrecisionMedicine #CancerResearch #BiotechInnovation #NorwegianHealthcare #InvestInNorway

Harnessing Gallic Acid & Resveratrol to Combat Triple-Negative Breast Cancer A new study highlights the potential of plant-derived compounds, gallic acid (GA) and resveratrol, in targeting triple-negative breast cancer (TNBC). Unlike conventional therapies, which often face challenges like drug resistance, this multi-target approach explores molecular docking with TNBC-associated receptors such as HER2, ER, PR, and BRCA1. 🧬 Why it matters: TNBC is one of the most aggressive breast cancer subtypes. Synergistic, less toxic alternatives are crucial to reducing recurrence and metastasis. 📖 DOI: https://lnkd.in/ehtM6tza #BreastCancerResearch #TripleNegativeBreastCancer #GallicAcid #Resveratrol #CancerTherapies

#KeiretsuBacked NuvOx Pharma continues to make groundbreaking strides in cancer treatment! Co-Founders Dr. Evan Unger and Dr. Jennifer L.H. Johnson recently published studies on their innovative drug candidate, NanO2™, exploring its oxygen delivery mechanism and a Phase 2b trial for aggressive brain cancer. This research solidifies NuvOx’s leadership in advancing cancer therapies. Learn more: https://lnkd.in/duBQd84V

👏 Thank you James Clubb for giving an excellent presentation on our promising clinical data on TILT-123 in combination with pembrolizumab for #OvarianCancer at the American Association for Cancer Research (AACR) Annual Meeting 2024 this week in San Diego! James demonstrated our phase 1 trial’s promising preliminary safety and efficacy results for platinum-resistant or refractory ovarian cancer patients, which highlight the potential of TILT-123 as an innovative cancer treatment by altering the tumor microenvironment and bolstering the body's immune response against cancer. We were delighted to see this included by Drug Discovery World in their highlights from #AACR24 piece: https://lnkd.in/e8-2kX36 📝 See the poster: https://lnkd.in/gHguit5C 🔗 Read our press release: https://lnkd.in/gewF3uTn #BioTech #Innovation #Oncology #ClinicalTrial

#Tarlatamab introduces T cells to cancer A bispecific antibody called Imdelltra (tarlatamab) that brings cancer cells and T cells into close proximity has been approved by the FDA for an aggressive type of #lungcancer. The drug binds to delta-like ligand 3, a molecule that is found on the surface of almost all small-cell lung cancer cells, but is not expressed on the surface of healthy cells. It simultaneously binds to the CD3 receptor on the T cell, bringing it close enough to the cancer cell to launch an attack. https://lnkd.in/gGeimjq8